Page 43 - Human Bile Acid Metabolism: a Postprandial Perspective

Postprandial bile acid concentrations
23. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics
study in an epidemiological setting. PLoS One. 2010;5(11):e13953.
24. Taylor DR, Alaghband-Zadeh J, Cross GF, Omar S, le Roux CW, Vincent RP. Urine bile acids relate to
glucose control in patients with type 2 diabetes mellitus and a body mass index below 30 kg/m2. PLoS
One. 2014;9(4):e93540. 2
25. Vincent RP, Omar S, Ghozlan S, et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem. 2013;50(Pt 4):360 –364.
26. Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes. 2013;62(12):4184 – 4191.
27. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab. 2015;100(3):E396 – E406.
28. Bisschop PH, Bandsma RH, Stellaard F, et al. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bileacid synthesis in humans. Am J Clin Nutr. 2004;79(4):570 –576.
29. Morton GJ, Kaiyala KJ, Foster-Schubert KE, Cummings DE, Schwartz MW. Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans. J Clin Endocrinol Metab. 2014;99(2):E241–E245.
30. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217–225.
31. Barutcuoglu B, Basol G, Cakir Y, et al. Fibroblast growth factor-19levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci. 2011;41(4):390 –396.
32. Fang Q, Li H, Song Q, et al. Serum fibroblast growth factor 19 levelsare decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care. 2013;36(9):2810 –2814.
33. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growthfactor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36(7):1859 –1864.
34. Mueller M, Thorell A, Claudel T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(6):1398 –1404.
35. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145(6):2594 –2603.
36. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143(5):1741–1747.
37. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 2011;13(6):729 –738.
38. Woerle HJ, Meyer C, Dostou JM, et al. Pathways for glucose disposal after meal ingestion in humans. Am J Physiol Endocrinol Metab. 2003;284(4):E716 –E725.
39. Hansen M, Scheltema MJ, Sonne DP, et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagonlike peptide-1 secretion. Diabetes Obes Metab. 2016;18(6):571– 580.
41